UBS lowered the firm’s price target on Elevance Health (ELV) to $425 from $435 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health: Buy Rating Maintained Amidst Mixed Business Segment Performance and Future Growth Prospects
- Mizuho views Elevance Health commentary as mixed, says estimates reflect risk
- Elevance Health falls after cautious comments on Medicaid margins
- Elevance Health Reaffirms 2025 Earnings Guidance
- Elevance Health price target raised to $373 from $327 at Barclays